^
    18h
    EX-TP: Examining the effect of exercise on tumour blood flow in women with breast cancer (ACTRN12625001315404)
    P=N/A, N=20, Suspended, University of the Sunshine Coast
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    20h
    Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Hebei Medical University Fourth Hospital
    New trial
    20h
    ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    HER-2 positive • ER positive • HER-2 negative • EGFR amplification • IDH wild-type • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • tolinapant (ASTX660)
    20h
    Cancer Exercise: Evaluation of a Mobile App in Breast Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=132, Completed, University of Alberta | Active, not recruiting --> Completed | N=200 --> 132
    Trial completion • Enrollment change
    20h
    Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=42, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: May 2028 --> May 2030 | Trial primary completion date: May 2026 --> May 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    20h
    HARMONIA: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (clinicaltrials.gov)
    P3, N=61, Terminated, SOLTI Breast Cancer Research Group | N=456 --> 61 | Trial completion date: Mar 2027 --> Mar 2026 | Active, not recruiting --> Terminated; The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.
    Enrollment change • Trial completion date • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test
    |
    Ibrance (palbociclib) • paclitaxel • Tevimbra (tislelizumab-jsgr) • Kisqali (ribociclib) • fulvestrant • letrozole
    20h
    Prospective Cohort Study of Local Recurrence After Radical Breast Cancer Resection (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    21h
    NuvastaticTM: Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=250, Recruiting, Natureceuticals Sdn Bhd
    New P3 trial
    21h
    The French E3N Prospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=100000, Active, not recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Dec 2025 --> Dec 2046
    Trial completion date
    22h
    Gender Disparities in Response to Neoadjuvant Therapy for Early-Stage Breast Cancer: A Propensity Score-Matched Analysis of the SEER Database. (PubMed, Breast Care (Basel))
    Men with early-stage breast cancer exhibit lower responsiveness to neoadjuvant therapy than women, particularly in human epidermal growth factor receptor 2-positive (HER2+) disease. However, survival equivalence among responders underscores the continued value of neoadjuvant therapy in MBC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR positive
    22h
    Feasibility of PIK3CA Mutation Detection via Microfluidic Isolation of Disseminated Tumor Cells from Bone Marrow in Breast Cancer Patients. (PubMed, Geburtshilfe Frauenheilkd)
    These findings suggest that current microfluidic enrichment methods, such as Parsortix, may be insufficient for reliable PIK3CA mutation detection in disseminated tumor cells. Additional research is required to investigate alternative enrichment techniques for the analysis of mutations in disseminated tumor cells.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    Parsortix Liquid Biopsy
    22h
    Recurrence Patterns and Overtreatment in Pure DCIS: A Retrospective Clinical and Radiological Follow-Up Study. (PubMed, J Pers Med)
    Traditional clinicopathological variables alone appeared insufficient to consistently identify recurrence patterns in this cohort. These findings support the need for more individualized risk stratification approaches integrating clinical, imaging, and molecular factors in order to reduce potential overtreatment in selected patients with DCIS.
    Retrospective data • Journal
    |
    ER (Estrogen receptor)
    |
    ER positive